Boothbay Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Boothbay Fund Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-30,600	Closed	-$14.2M	–	1938
2024 Q3	$14.2M	Buy	+30,600	New	+$14.7M	0.32%	39
2021 Q2	–	Sell	-235	Closed	-$5.05M	–	2140
2021 Q1	$5.05M	Buy	+235	New	+$51.6K	0.19%	98
2019 Q2	–	Sell	-42	Closed	-$773K	–	908
2019 Q1	$773K	Sell	42 -244	-85%	-$45.1K	0.07%	287
2018 Q4	$4.74M	Buy	+286	New	+$49.6K	0.69%	25
2016 Q3	–	Sell	-3,800	Closed	-$327K	–	812
2016 Q2	$327K	Buy	+3,800	New	+$328K	0.13%	226

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Boothbay Fund Management's VRTX Position: Q2 2026 in Review

Boothbay Fund Management increased its Vertex Pharmaceuticals (VRTX) stake by 368% in Q2 2026, buying an estimated $2.15M and bringing the position to 6,174 shares worth $3.07M. The position accounts for 0.04% of the portfolio, ranked #523.

Boothbay Fund Management first reported a position in VRTX in Q1 2017 and has held it in 17 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Boothbay Fund Management held 6,174 shares of Vertex Pharmaceuticals worth $3.07M as of Q2 2026.
Boothbay Fund Management bought 4,854 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.15M.
Vertex Pharmaceuticals made up 0.04% of Boothbay Fund Management's portfolio in Q2 2026, its #523 holding.
Boothbay Fund Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 17 quarters since.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.